Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human SAD, Mass Balance, and Food Effect Study of ABBV-1088 in Healthy Volunteers
NCT06414798Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MTK458 in Parkinson's disease (PD) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration at 11 days, Time to Maximum Plasma Concentration at 11 days and 5 more. Started May 2024; status: completed.
02
Drugs
MTK458
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06414798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414798.